Mumbai: Pharmaceutical major Alkem Laboratories Limited reported a 14.4% year-on-year decline in consolidated net profit to ₹667.1 crore for the quarter ended September 30, 2026, compared with ₹779.1 crore in the corresponding quarter last year.
Despite the decline in profitability, the company's revenue from operations increased 13.8% to ₹4,552 crore from ₹4,001 crore a year earlier, according to its exchange filing on Thursday.
Revenue Growth
Alkem's total consolidated income rose 14.2% to ₹4,686 crore in Q2 FY27 from ₹4,105 crore in Q2 FY26. However, total expenses increased 16% to ₹3,722 crore from ₹3,209 crore, outpacing revenue growth. Profit before tax increased 11.6% to ₹999.7 crore from ₹895.8 crore in the year-ago quarter. The company reported tax expenses of ₹331.9 crore, compared with ₹116.2 crore a year earlier, weighing on its bottom line.
Sequential Performance
On a quarter-on-quarter basis, consolidated net profit increased 28% from ₹521 crore in the April-June quarter. Revenue from operations rose 21.7% sequentially from ₹3,740 crore, reflecting stronger quarterly sales. Basic earnings per share stood at ₹56.48, compared with ₹63.99 in the corresponding quarter last year.
Half-Year Performance
For the first six months of FY27, Alkem reported consolidated revenue of ₹8,292 crore, up 12.5% from ₹7,372 crore in the corresponding period last year. However, consolidated net profit declined 17.9% to ₹1,188 crore from ₹1,447 crore.
Segment Performance
The pharmaceuticals segment generated revenue of ₹4,347.9 crore during the quarter, compared with ₹3,890 crore a year earlier. The Biotech segment reported revenue of ₹129.8 crore, while MedTech revenue stood at ₹133.1 crore. Biotech recorded a segment loss of ₹114.1 crore, while MedTech reported a loss of ₹49.6 crore.
Meanwhile, Alkem completed the acquisition of a 55% stake in Switzerland-based Occlutech Holding AG in July 2026, with its financial results consolidated from July 16. The company also recognised an exceptional gain of ₹35 crore from recovery against a previously impaired investment. The board approved the unaudited financial results on November 12, 2026.
Level up your brain the fun way. Play daily games and quizzes on FPJ Smart!
